Aly Elezaby1, Aaron L Sverdlov1, Vivian H Tu1, Kanupriya Soni1, Ivan Luptak1, Fuzhong Qin1, Marc Liesa2, Orian S Shirihai2, Jamie Rimer3, Jean E Schaffer3, Wilson S Colucci1, Edward J Miller4. 1. Boston University School of Medicine, Whitaker Cardiovascular Institute, Section of Cardiovascular Medicine, Boston, MA 02118, United States. 2. Boston University School of Medicine, Obesity and Nutrition Section, Department of Medicine, Boston, MA 02118, United States. 3. Washington University School of Medicine, Diabetic Cardiovascular Disease Center, St Louis, MO 63110, United States. 4. Boston University School of Medicine, Whitaker Cardiovascular Institute, Section of Cardiovascular Medicine, Boston, MA 02118, United States. Electronic address: ejmiller@bu.edu.
Abstract
BACKGROUND: Obesity leads to metabolic heart disease (MHD) that is associated with a pathologic increase in myocardial fatty acid (FA) uptake and impairment of mitochondrial function. The mechanism of mitochondrial dysfunction in MHD, which results in oxidant production and decreased energetics, is poorly understood but may be related to excess FAs. Determining the effects of cardiac FA excess on mitochondria can be hindered by the systemic sequelae of obesity. Mice with cardiomyocyte-specific overexpression of the fatty acid transport protein FATP1 have increased cardiomyocyte FA uptake and develop MHD in the absence of systemic lipotoxicity, obesity or diabetes. We utilized this model to assess 1) the effect of cardiomyocyte lipid accumulation on mitochondrial structure and energetic function and 2) the role of lipid-driven transcriptional regulation, signaling, toxic metabolite accumulation, and mitochondrial oxidative stress in lipid-induced MHD. METHODS: Cardiac lipid species, lipid-dependent signaling, and mitochondrial structure/function were examined from FATP1 mice. Cardiac structure and function were assessed in mice overexpressing both FATP1 and mitochondrial-targeted catalase. RESULTS: FATP1 hearts exhibited a net increase (+12%) in diacylglycerol, with increases in several very long-chain diacylglycerol species (+160-212%, p<0.001) and no change in ceramide, sphingomyelin, or acylcarnitine content. This was associated with an increase in phosphorylation of PKCα and PKCδ, and a decrease in phosphorylation of AKT and expression of CREB, PGC1α, PPARα and the mitochondrial fusion genes MFN1, MFN2 and OPA1. FATP1 overexpression also led to marked decreases in mitochondrial size (-49%, p<0.01), complex II-driven respiration (-28.6%, p<0.05), activity of isolated complex II (-62%, p=0.05), and expression of complex II subunit B (SDHB) (-60% and -31%, p<0.01) in the absence of change in ATP synthesis. Hydrogen peroxide production was not increased in FATP1 mitochondria, and cardiac hypertrophy and diastolic dysfunction were not attenuated by overexpression of catalase in mitochondria in FATP1 mice. CONCLUSIONS: Excessive delivery of FAs to the cardiac myocyte in the absence of systemic disorders leads to activation of lipid-driven signaling and remodeling of mitochondrial structure and function.
BACKGROUND:Obesity leads to metabolic heart disease (MHD) that is associated with a pathologic increase in myocardial fatty acid (FA) uptake and impairment of mitochondrial function. The mechanism of mitochondrial dysfunction in MHD, which results in oxidant production and decreased energetics, is poorly understood but may be related to excess FAs. Determining the effects of cardiac FA excess on mitochondria can be hindered by the systemic sequelae of obesity. Mice with cardiomyocyte-specific overexpression of the fatty acid transport protein FATP1 have increased cardiomyocyte FA uptake and develop MHD in the absence of systemic lipotoxicity, obesity or diabetes. We utilized this model to assess 1) the effect of cardiomyocyte lipid accumulation on mitochondrial structure and energetic function and 2) the role of lipid-driven transcriptional regulation, signaling, toxic metabolite accumulation, and mitochondrial oxidative stress in lipid-induced MHD. METHODS: Cardiac lipid species, lipid-dependent signaling, and mitochondrial structure/function were examined from FATP1mice. Cardiac structure and function were assessed in mice overexpressing both FATP1 and mitochondrial-targeted catalase. RESULTS:FATP1 hearts exhibited a net increase (+12%) in diacylglycerol, with increases in several very long-chain diacylglycerol species (+160-212%, p<0.001) and no change in ceramide, sphingomyelin, or acylcarnitine content. This was associated with an increase in phosphorylation of PKCα and PKCδ, and a decrease in phosphorylation of AKT and expression of CREB, PGC1α, PPARα and the mitochondrial fusion genes MFN1, MFN2 and OPA1. FATP1 overexpression also led to marked decreases in mitochondrial size (-49%, p<0.01), complex II-driven respiration (-28.6%, p<0.05), activity of isolated complex II (-62%, p=0.05), and expression of complex II subunit B (SDHB) (-60% and -31%, p<0.01) in the absence of change in ATP synthesis. Hydrogen peroxide production was not increased in FATP1 mitochondria, and cardiac hypertrophy and diastolic dysfunction were not attenuated by overexpression of catalase in mitochondria in FATP1mice. CONCLUSIONS: Excessive delivery of FAs to the cardiac myocyte in the absence of systemic disorders leads to activation of lipid-driven signaling and remodeling of mitochondrial structure and function.
Authors: Fuzhong Qin; Deborah A Siwik; Ivan Luptak; Xiuyun Hou; Lei Wang; Akiko Higuchi; Robert M Weisbrod; Noriyuki Ouchi; Vivian H Tu; Timothy D Calamaras; Edward J Miller; Tony J Verbeuren; Kenneth Walsh; Richard A Cohen; Wilson S Colucci Journal: Circulation Date: 2012-03-02 Impact factor: 29.690
Authors: Marc Liesa; Ivan Luptak; Fuzhong Qin; Brigham B Hyde; Ergun Sahin; Deborah A Siwik; Zhengkun Zhu; David R Pimentel; X Julia Xu; Neil B Ruderman; Karl D Huffman; Susan R Doctrow; Lauren Richey; Wilson S Colucci; Orian S Shirihai Journal: Circulation Date: 2011-07-25 Impact factor: 29.690
Authors: Florian L Muller; Yuhong Liu; Muhammad A Abdul-Ghani; Michael S Lustgarten; Arunabh Bhattacharya; Youngmok C Jang; Holly Van Remmen Journal: Biochem J Date: 2008-01-15 Impact factor: 3.857
Authors: Erinne R Dabkowski; Walter A Baseler; Courtney L Williamson; Matthew Powell; Trust T Razunguzwa; Jefferson C Frisbee; John M Hollander Journal: Am J Physiol Heart Circ Physiol Date: 2010-06-11 Impact factor: 4.733
Authors: Vanessa García-Rúa; Manuel Francisco Otero; Pamela Virginia Lear; Diego Rodríguez-Penas; Sandra Feijóo-Bandín; Teresa Noguera-Moreno; Manuel Calaza; María Álvarez-Barredo; Ana Mosquera-Leal; John Parrington; Josep Brugada; Manuel Portolés; Miguel Rivera; José Ramón González-Juanatey; Francisca Lago Journal: PLoS One Date: 2012-06-06 Impact factor: 3.240
Authors: Lene Nygaard Axelsen; Kirstine Calloe; Thomas Hartig Braunstein; Mads Riemann; Johannes Pauli Hofgaard; Bo Liang; Christa Funch Jensen; Kristine Boisen Olsen; Emil D Bartels; Ulrik Baandrup; Thomas Jespersen; Lars Bo Nielsen; Niels-Henrik Holstein-Rathlou; Morten Schak Nielsen Journal: Cardiovasc Diabetol Date: 2015-07-14 Impact factor: 9.951
Authors: Olufemi I Oluranti; Ebunoluwa A Agboola; Nteimam E Fubara; Mercy O Ajayi; Olugbenga S Michael Journal: Ann Med Date: 2021-12 Impact factor: 4.709